New Data Presented at SABCS 2021 Strengthen Value of Oncoty

New Data Presented at SABCS 2021 Strengthen Value of Oncotype DX Breast Recurrence Score® Test to Inform Clinical Decision-making Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy...

Related Keywords

San Antonio , Texas , United States , Kevin Kalinsky , Rick Baehner , Sciences Corp , National Cancer Institute , Cancer Research Network , Facebook , Precision Oncology At Exact Sciences , Sciences On Twitter Exactsciences , Nasdaq , New Data Presented , Inform Clinical , Exact Sciences , Antonio Breast Cancer , Recurrence Score , Research Network , Precision Oncology , New England Journal , North East England , Freeman Hospital , Newcastle University , Princess Margaret Trial , Poster Sessions , Spotlight Poster Discussions , Using Oncotype , Pan Cancer Tissue ,